Gene7的个人主页 - 老虎社区

Gene7

Gene7

暂无个人介绍

IP属地：海外

18关注

0粉丝

0主题

0勋章

2021-12-10

Noted with thanks. Like plz

10 Biggest Price Target Changes For Thursday

2021-12-08

Thanks for the insight. Plz like

Pfizer, BioNTech say third dose neutralizes Omicron variant

2021-10-30

Thank you for the info. Plz like.

US stocks fall after Big Tech earnings miss, Amazon down 4%

2021-12-23

Thanks for the insight. Plz like. [lovely]

抱歉，原内容已删除

2021-10-30

[强]

抱歉，原内容已删除

2021-08-24

[强] Thank you

抱歉，原内容已删除

2021-11-27

Thanks for the insight. Plz like [lovely]

Worried About A Market Crash? Here Are 3 Things You Can Do

2021-11-30

Thank you for the insight. Plz like. [lovely]

Toplines Before US Market Open on Monday

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4088056512769340","uuid":"4088056512769340","gmtCreate":1625147614300,"gmtModify":1629859237802,"name":"Gene7","pinyin":"gene7","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/6104ceb59a974d144154c2afbaf6e10b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":18,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.13","exceedPercentage":"80.63%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"海外","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":691296063,"gmtCreate":1640190878449,"gmtModify":1640190879600,"author":{"id":"4088056512769340","authorId":"4088056512769340","name":"Gene7","avatar":"https://static.tigerbbs.com/6104ceb59a974d144154c2afbaf6e10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088056512769340","authorIdStr":"4088056512769340"},"themes":[],"htmlText":"Thanks for the insight. Plz like.&nbsp;[lovely]&nbsp;","listText":"Thanks for the insight. Plz like.&nbsp;[lovely]&nbsp;","text":"Thanks for the insight. Plz like. [lovely]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691296063","repostId":"2193196162","repostType":4,"repost":{"id":"2193196162","pubTimestamp":1640179320,"share":"https://www.laohu8.com/m/news/2193196162?lang=&edition=full","pubTime":"2021-12-22 21:22","market":"us","language":"en","title":"The Fed Just Gave These 3 Stocks a Boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2193196162","media":"Motley Fool","summary":"After market close on Dec. 17, the Federal Reserve signed off on three bank mergers that have been in their pipeline.","content":"<p>At the end of the day on Friday, Dec. 17, the Federal Reserve approved three bank mergers that had been in its backlog. The approvals came as a bit of a surprise -- not because I didn't think they would get approved, but because I thought they might be pushed off until next year due to the changing regulatory landscape in Washington, where regulators and lawmakers have been tussling over large bank mergers and how they are scrutinized. The recent approvals bode well not only for the parties involved but also for other larger bank mergers in the pipeline.</p>\n<p>Let's take a look at these three deals and how investors may be thinking about them.</p>\n<h2>1. First Citizens' acquisition of CIT Group</h2>\n<p>In perhaps the most significant approval, the Federal Reserve finally signed off on <b>First Citizens Bancshares'</b> (NASDAQ:FCNCA) planned acquisition of <b>CIT Group</b> (NYSE:CIT). The deal, announced in October 2020, was first expected to close in the first half of 2021. But after months of delay, First Citizens and CIT were forced to extend their merger agreement to March 2022. The acquisition will grow First Citizens to about $111 billion of assets.</p>\n<p>This approval is huge because investors loved this deal right off the bat and have been driving up First Citizens' stock price ever since. The acquisition is expected to grow First Citizens' earnings per share next year by more than 50% and its tangible book value (TBV, what a bank would be worth if it were liquidated), by more than 30%. Both of those numbers are considered massive for a bank deal. Since announcing the deal, First Citizens' stock is up about 95%, and I believe investors are valuing the bank based on its new TBV. So, if the deal had not gone through, I think the stock price would have gotten knocked down considerably.</p>\n<h2>2. Webster's acquisition of <a href=\"https://laohu8.com/S/STL\">Sterling Bancorp</a></h2>\n<p>In April, <b><a href=\"https://laohu8.com/S/WBS\">Webster Financial Corp</a>.</b>&nbsp;(NYSE:WBS), based in Connecticut, announced its plan to merge with <b>Sterling Bancorp</b> (NYSE:STL) of New York in a deal that will create a regional bank with nearly $66 billion in assets. Webster recently announced that it now expects the deal to close on Feb. 1, 2022, which is still a few months after its initial closing projection before the end of the year. Still, given the way things had been trending, and with the competing tones over bank mergers in Washington and backlog of pending deals at the Fed, this should relieve any concerns among investors that the deal might not go through.</p>\n<p>The market did not like this deal when it was announced, likely because both Webster and Sterling were already strong-performing banks, and it seems like the market saw this as a bit of a gamble in terms of strategic direction. While the deal has a lot of execution risk, I think there is some good potential here. The deal will enable Webster to invest more into its health savings account business, which is a main driver of deposits at the bank, along with Sterling's up-and-coming banking-as-a-service capabilities.</p>\n<h2>3. WSFS' acquisition of Bryn Mawr Bank</h2>\n<p>The other deal the Fed approved last Friday was <b>WSFS Financial Corp.</b>'s (NASDAQ:WSFS)&nbsp;acquisition of&nbsp;<b>Bryn Mawr Bank</b> (NASDAQ:BMTC). The approval of this deal is not as surprising as the others because the transaction will only create a roughly $20 billion asset bank on the Pennsylvania-Delaware border. The deal is now expected to close on Jan. 1, which is slightly delayed from when it was supposed to have closed in the early part of the current quarter. The acquisition creates an attractive bank for shareholders that will have strong core fee revenue and a good deposit base. The combination of WSFS and Bryn Mawr also creates a strong wealth management franchise with $43 billion in assets under management.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Fed Just Gave These 3 Stocks a Boost</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Fed Just Gave These 3 Stocks a Boost\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 21:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/the-fed-just-gave-these-3-stocks-a-boost/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>At the end of the day on Friday, Dec. 17, the Federal Reserve approved three bank mergers that had been in its backlog. The approvals came as a bit of a surprise -- not because I didn't think they ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/the-fed-just-gave-these-3-stocks-a-boost/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CIT":"CIT Group Inc","WSFS":"WSFS金融","WBS":"韦伯斯特金融","BMTC":"布林摩尔银行","FCNCA":"第一公民银行股份"},"source_url":"https://www.fool.com/investing/2021/12/22/the-fed-just-gave-these-3-stocks-a-boost/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193196162","content_text":"At the end of the day on Friday, Dec. 17, the Federal Reserve approved three bank mergers that had been in its backlog. The approvals came as a bit of a surprise -- not because I didn't think they would get approved, but because I thought they might be pushed off until next year due to the changing regulatory landscape in Washington, where regulators and lawmakers have been tussling over large bank mergers and how they are scrutinized. The recent approvals bode well not only for the parties involved but also for other larger bank mergers in the pipeline.\nLet's take a look at these three deals and how investors may be thinking about them.\n1. First Citizens' acquisition of CIT Group\nIn perhaps the most significant approval, the Federal Reserve finally signed off on First Citizens Bancshares' (NASDAQ:FCNCA) planned acquisition of CIT Group (NYSE:CIT). The deal, announced in October 2020, was first expected to close in the first half of 2021. But after months of delay, First Citizens and CIT were forced to extend their merger agreement to March 2022. The acquisition will grow First Citizens to about $111 billion of assets.\nThis approval is huge because investors loved this deal right off the bat and have been driving up First Citizens' stock price ever since. The acquisition is expected to grow First Citizens' earnings per share next year by more than 50% and its tangible book value (TBV, what a bank would be worth if it were liquidated), by more than 30%. Both of those numbers are considered massive for a bank deal. Since announcing the deal, First Citizens' stock is up about 95%, and I believe investors are valuing the bank based on its new TBV. So, if the deal had not gone through, I think the stock price would have gotten knocked down considerably.\n2. Webster's acquisition of Sterling Bancorp\nIn April, Webster Financial Corp. (NYSE:WBS), based in Connecticut, announced its plan to merge with Sterling Bancorp (NYSE:STL) of New York in a deal that will create a regional bank with nearly $66 billion in assets. Webster recently announced that it now expects the deal to close on Feb. 1, 2022, which is still a few months after its initial closing projection before the end of the year. Still, given the way things had been trending, and with the competing tones over bank mergers in Washington and backlog of pending deals at the Fed, this should relieve any concerns among investors that the deal might not go through.\nThe market did not like this deal when it was announced, likely because both Webster and Sterling were already strong-performing banks, and it seems like the market saw this as a bit of a gamble in terms of strategic direction. While the deal has a lot of execution risk, I think there is some good potential here. The deal will enable Webster to invest more into its health savings account business, which is a main driver of deposits at the bank, along with Sterling's up-and-coming banking-as-a-service capabilities.\n3. WSFS' acquisition of Bryn Mawr Bank\nThe other deal the Fed approved last Friday was WSFS Financial Corp.'s (NASDAQ:WSFS) acquisition of Bryn Mawr Bank (NASDAQ:BMTC). The approval of this deal is not as surprising as the others because the transaction will only create a roughly $20 billion asset bank on the Pennsylvania-Delaware border. The deal is now expected to close on Jan. 1, which is slightly delayed from when it was supposed to have closed in the early part of the current quarter. The acquisition creates an attractive bank for shareholders that will have strong core fee revenue and a good deposit base. The combination of WSFS and Bryn Mawr also creates a strong wealth management franchise with $43 billion in assets under management.","news_type":1},"isVote":1,"tweetType":1,"viewCount":698,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602716372,"gmtCreate":1639066085017,"gmtModify":1639066085017,"author":{"id":"4088056512769340","authorId":"4088056512769340","name":"Gene7","avatar":"https://static.tigerbbs.com/6104ceb59a974d144154c2afbaf6e10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088056512769340","authorIdStr":"4088056512769340"},"themes":[],"htmlText":"Noted with thanks. Like plz","listText":"Noted with thanks. Like plz","text":"Noted with thanks. Like plz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/602716372","repostId":"1134628800","repostType":4,"repost":{"id":"1134628800","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1639064594,"share":"https://www.laohu8.com/m/news/1134628800?lang=&edition=full","pubTime":"2021-12-09 23:43","market":"us","language":"en","title":"10 Biggest Price Target Changes For Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1134628800","media":"Benzinga","summary":"SVB Leerink boosted the price target on Edwards Lifesciences Corporation from $130 to $135. Edwards ","content":"<ul>\n <li>SVB Leerink boosted the price target on&nbsp;<b>Edwards Lifesciences Corporation</b>&nbsp;from $130 to $135. Edwards Lifesciences shares rose 1% to trade at $120.68 on Thursday.</li>\n <li>Keybanc raised&nbsp;<b>The Sherwin-Williams Company</b>&nbsp;price target from $350 to $384. Sherwin-Williams shares rose 1% to $345.68 on Thursday.</li>\n <li>Piper Sandler cut&nbsp;<b>Udemy, Inc.</b>&nbsp;price target from $37 to $34. Udemy shares fell 2% to trade at $20.65 on Thursday.</li>\n <li>Needham lowered the price target on&nbsp;<b>Esperion Therapeutics, Inc.</b>&nbsp;from $20 to $12. Esperion Therapeutics shares dropped 9% to $5.34 on Thursday.</li>\n <li>JP Morgan lifted&nbsp;<b>Phillips 66</b>&nbsp;price target from $83 to $93. Phillips 66 shares rose 0.7% to $72.36 on Thursday.</li>\n <li>RBC Capital cut the price target for&nbsp;<b>Cincinnati Financial Corporation</b>&nbsp;from $135 to $130. Cincinnati Financial shares fell 1.7% to $115.23 on Thursday.</li>\n <li>Chardan Capital raised&nbsp;<b>Dicerna Pharmaceuticals, Inc.</b>&nbsp;price target from $28 to $38.25. Dicerna Pharmaceuticals shares rose 0.1% to $38.03 on Thursday.</li>\n <li>Morgan Stanley boosted the price target on&nbsp;<b>Oshkosh Corporation</b>&nbsp;from $134 to $144. Oshkosh shares fell 1.4% to trade at $111.45 on Thursday.</li>\n <li>Wells Fargo cut the price target for&nbsp;<b>Dow Inc.</b>&nbsp;from $75 to $67. Dow shares fell 0.8% to $54.49 on Thursday.</li>\n <li>Barclays raised&nbsp;<b>McKesson Corporation</b>&nbsp;price target from $270 to $290. McKesson shares rose 1.1% to $229.33 on Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-09 23:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>SVB Leerink boosted the price target on&nbsp;<b>Edwards Lifesciences Corporation</b>&nbsp;from $130 to $135. Edwards Lifesciences shares rose 1% to trade at $120.68 on Thursday.</li>\n <li>Keybanc raised&nbsp;<b>The Sherwin-Williams Company</b>&nbsp;price target from $350 to $384. Sherwin-Williams shares rose 1% to $345.68 on Thursday.</li>\n <li>Piper Sandler cut&nbsp;<b>Udemy, Inc.</b>&nbsp;price target from $37 to $34. Udemy shares fell 2% to trade at $20.65 on Thursday.</li>\n <li>Needham lowered the price target on&nbsp;<b>Esperion Therapeutics, Inc.</b>&nbsp;from $20 to $12. Esperion Therapeutics shares dropped 9% to $5.34 on Thursday.</li>\n <li>JP Morgan lifted&nbsp;<b>Phillips 66</b>&nbsp;price target from $83 to $93. Phillips 66 shares rose 0.7% to $72.36 on Thursday.</li>\n <li>RBC Capital cut the price target for&nbsp;<b>Cincinnati Financial Corporation</b>&nbsp;from $135 to $130. Cincinnati Financial shares fell 1.7% to $115.23 on Thursday.</li>\n <li>Chardan Capital raised&nbsp;<b>Dicerna Pharmaceuticals, Inc.</b>&nbsp;price target from $28 to $38.25. Dicerna Pharmaceuticals shares rose 0.1% to $38.03 on Thursday.</li>\n <li>Morgan Stanley boosted the price target on&nbsp;<b>Oshkosh Corporation</b>&nbsp;from $134 to $144. Oshkosh shares fell 1.4% to trade at $111.45 on Thursday.</li>\n <li>Wells Fargo cut the price target for&nbsp;<b>Dow Inc.</b>&nbsp;from $75 to $67. Dow shares fell 0.8% to $54.49 on Thursday.</li>\n <li>Barclays raised&nbsp;<b>McKesson Corporation</b>&nbsp;price target from $270 to $290. McKesson shares rose 1.1% to $229.33 on Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CINF":"辛辛那提金融","OSK":"Oshkosh","EW":"爱德华兹","MCK":"麦克森药物批发","UDMY":"Udemy, Inc.","DRNA":"Dicerna Pharmaceuticals, Inc.","SHW":"宣伟公司","ESPR":"Esperion Therapeutics Inc.","PSX":"Phillips 66","DOW":"陶氏化学"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134628800","content_text":"SVB Leerink boosted the price target on Edwards Lifesciences Corporation from $130 to $135. Edwards Lifesciences shares rose 1% to trade at $120.68 on Thursday.\nKeybanc raised The Sherwin-Williams Company price target from $350 to $384. Sherwin-Williams shares rose 1% to $345.68 on Thursday.\nPiper Sandler cut Udemy, Inc. price target from $37 to $34. Udemy shares fell 2% to trade at $20.65 on Thursday.\nNeedham lowered the price target on Esperion Therapeutics, Inc. from $20 to $12. Esperion Therapeutics shares dropped 9% to $5.34 on Thursday.\nJP Morgan lifted Phillips 66 price target from $83 to $93. Phillips 66 shares rose 0.7% to $72.36 on Thursday.\nRBC Capital cut the price target for Cincinnati Financial Corporation from $135 to $130. Cincinnati Financial shares fell 1.7% to $115.23 on Thursday.\nChardan Capital raised Dicerna Pharmaceuticals, Inc. price target from $28 to $38.25. Dicerna Pharmaceuticals shares rose 0.1% to $38.03 on Thursday.\nMorgan Stanley boosted the price target on Oshkosh Corporation from $134 to $144. Oshkosh shares fell 1.4% to trade at $111.45 on Thursday.\nWells Fargo cut the price target for Dow Inc. from $75 to $67. Dow shares fell 0.8% to $54.49 on Thursday.\nBarclays raised McKesson Corporation price target from $270 to $290. McKesson shares rose 1.1% to $229.33 on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1076,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602329083,"gmtCreate":1638974252750,"gmtModify":1638974252750,"author":{"id":"4088056512769340","authorId":"4088056512769340","name":"Gene7","avatar":"https://static.tigerbbs.com/6104ceb59a974d144154c2afbaf6e10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088056512769340","authorIdStr":"4088056512769340"},"themes":[],"htmlText":"Thanks for the insight. Plz like&nbsp;","listText":"Thanks for the insight. Plz like&nbsp;","text":"Thanks for the insight. Plz like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/602329083","repostId":"1177589023","repostType":4,"repost":{"id":"1177589023","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638964838,"share":"https://www.laohu8.com/m/news/1177589023?lang=&edition=full","pubTime":"2021-12-08 20:00","market":"us","language":"en","title":"Pfizer, BioNTech say third dose neutralizes Omicron variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1177589023","media":"Tiger Newspress","summary":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on ","content":"<p>Pfizer and biontech stocks narrowed their losses&nbsp;in premarket trading&nbsp;after&nbsp;they provided update on Omicron variant.</p>\n<p><img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li>\n <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li>\n <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li>\n <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li>\n</ul>\n<p>Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;today announced results from an initial&nbsp;<i>laboratory</i>&nbsp;study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p>\n<p>Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p>\n<p>A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p>\n<p>“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said&nbsp;<b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p>\n<p>“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said&nbsp;<b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p>\n<p>While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta &amp; Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, BioNTech say third dose neutralizes Omicron variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, BioNTech say third dose neutralizes Omicron variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer and biontech stocks narrowed their losses&nbsp;in premarket trading&nbsp;after&nbsp;they provided update on Omicron variant.</p>\n<p><img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li>\n <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li>\n <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li>\n <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li>\n</ul>\n<p>Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;today announced results from an initial&nbsp;<i>laboratory</i>&nbsp;study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p>\n<p>Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p>\n<p>A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p>\n<p>“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said&nbsp;<b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p>\n<p>“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said&nbsp;<b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p>\n<p>While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta &amp; Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177589023","content_text":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on Omicron variant.\n\n\nPreliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers\nData indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection\nAs 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease\nThe companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022\n\nPfizer Inc. and BioNTech SE today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.\nSera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.\nA more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.\n“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”\n“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”\nWhile these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta & Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1074,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609000596,"gmtCreate":1638202355191,"gmtModify":1638202355389,"author":{"id":"4088056512769340","authorId":"4088056512769340","name":"Gene7","avatar":"https://static.tigerbbs.com/6104ceb59a974d144154c2afbaf6e10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088056512769340","authorIdStr":"4088056512769340"},"themes":[],"htmlText":"Thank you for the insight. Plz like.&nbsp;[lovely]&nbsp;","listText":"Thank you for the insight. Plz like.&nbsp;[lovely]&nbsp;","text":"Thank you for the insight. Plz like. [lovely]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609000596","repostId":"1115824573","repostType":4,"isVote":1,"tweetType":1,"viewCount":935,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877792253,"gmtCreate":1637980482856,"gmtModify":1637980482856,"author":{"id":"4088056512769340","authorId":"4088056512769340","name":"Gene7","avatar":"https://static.tigerbbs.com/6104ceb59a974d144154c2afbaf6e10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088056512769340","authorIdStr":"4088056512769340"},"themes":[],"htmlText":"Thanks for the insight. Plz like&nbsp;[lovely]&nbsp;","listText":"Thanks for the insight. Plz like&nbsp;[lovely]&nbsp;","text":"Thanks for the insight. Plz like [lovely]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877792253","repostId":"1100178242","repostType":4,"isVote":1,"tweetType":1,"viewCount":819,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857295821,"gmtCreate":1635526088394,"gmtModify":1635526088394,"author":{"id":"4088056512769340","authorId":"4088056512769340","name":"Gene7","avatar":"https://static.tigerbbs.com/6104ceb59a974d144154c2afbaf6e10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088056512769340","authorIdStr":"4088056512769340"},"themes":[],"htmlText":"Thank you for the info.&nbsp;Plz like.&nbsp;","listText":"Thank you for the info.&nbsp;Plz like.&nbsp;","text":"Thank you for the info. Plz like.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857295821","repostId":"1130577261","repostType":4,"isVote":1,"tweetType":1,"viewCount":1116,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857298267,"gmtCreate":1635525881392,"gmtModify":1635525881392,"author":{"id":"4088056512769340","authorId":"4088056512769340","name":"Gene7","avatar":"https://static.tigerbbs.com/6104ceb59a974d144154c2afbaf6e10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088056512769340","authorIdStr":"4088056512769340"},"themes":[],"htmlText":"[强]&nbsp;","listText":"[强]&nbsp;","text":"[强]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857298267","repostId":"1147653984","repostType":4,"repost":{"id":"1147653984","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635516830,"share":"https://www.laohu8.com/m/news/1147653984?lang=&edition=full","pubTime":"2021-10-29 22:13","market":"us","language":"en","title":"Tesla's shares price reached 1100 dollars and its market value exceeded over 1.1 trillion dollars","url":"https://stock-news.laohu8.com/highlight/detail?id=1147653984","media":"Tiger Newspress","summary":"Tesla's shares price reached 1100 dollars and its market value exceeded over 1.1 trillion dollars.Th","content":"<p>Tesla's shares price reached 1100 dollars and its market value exceeded over 1.1 trillion dollars.<img src=\"https://static.tigerbbs.com/6bb955d6a1040e777a3b731000c0df75\" tg-width=\"772\" tg-height=\"572\" width=\"100%\" height=\"auto\">The interim CEO of Hertz, a car rental company, said that it may increase the order of Tesla Motors electric vehicles to 200,000.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla's shares price reached 1100 dollars and its market value exceeded over 1.1 trillion dollars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla's shares price reached 1100 dollars and its market value exceeded over 1.1 trillion dollars\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-29 22:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tesla's shares price reached 1100 dollars and its market value exceeded over 1.1 trillion dollars.<img src=\"https://static.tigerbbs.com/6bb955d6a1040e777a3b731000c0df75\" tg-width=\"772\" tg-height=\"572\" width=\"100%\" height=\"auto\">The interim CEO of Hertz, a car rental company, said that it may increase the order of Tesla Motors electric vehicles to 200,000.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147653984","content_text":"Tesla's shares price reached 1100 dollars and its market value exceeded over 1.1 trillion dollars.The interim CEO of Hertz, a car rental company, said that it may increase the order of Tesla Motors electric vehicles to 200,000.","news_type":1},"isVote":1,"tweetType":1,"viewCount":630,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":834540213,"gmtCreate":1629815409332,"gmtModify":1633682240611,"author":{"id":"4088056512769340","authorId":"4088056512769340","name":"Gene7","avatar":"https://static.tigerbbs.com/6104ceb59a974d144154c2afbaf6e10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088056512769340","authorIdStr":"4088056512769340"},"themes":[],"htmlText":"[强]&nbsp;Thank you&nbsp;","listText":"[强]&nbsp;Thank you&nbsp;","text":"[强] Thank you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/834540213","repostId":"1183629667","repostType":4,"isVote":1,"tweetType":1,"viewCount":760,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":602716372,"gmtCreate":1639066085017,"gmtModify":1639066085017,"author":{"id":"4088056512769340","authorId":"4088056512769340","name":"Gene7","avatar":"https://static.tigerbbs.com/6104ceb59a974d144154c2afbaf6e10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088056512769340","authorIdStr":"4088056512769340"},"themes":[],"htmlText":"Noted with thanks. Like plz","listText":"Noted with thanks. Like plz","text":"Noted with thanks. Like plz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/602716372","repostId":"1134628800","repostType":4,"repost":{"id":"1134628800","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1639064594,"share":"https://www.laohu8.com/m/news/1134628800?lang=&edition=full","pubTime":"2021-12-09 23:43","market":"us","language":"en","title":"10 Biggest Price Target Changes For Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1134628800","media":"Benzinga","summary":"SVB Leerink boosted the price target on Edwards Lifesciences Corporation from $130 to $135. Edwards ","content":"<ul>\n <li>SVB Leerink boosted the price target on&nbsp;<b>Edwards Lifesciences Corporation</b>&nbsp;from $130 to $135. Edwards Lifesciences shares rose 1% to trade at $120.68 on Thursday.</li>\n <li>Keybanc raised&nbsp;<b>The Sherwin-Williams Company</b>&nbsp;price target from $350 to $384. Sherwin-Williams shares rose 1% to $345.68 on Thursday.</li>\n <li>Piper Sandler cut&nbsp;<b>Udemy, Inc.</b>&nbsp;price target from $37 to $34. Udemy shares fell 2% to trade at $20.65 on Thursday.</li>\n <li>Needham lowered the price target on&nbsp;<b>Esperion Therapeutics, Inc.</b>&nbsp;from $20 to $12. Esperion Therapeutics shares dropped 9% to $5.34 on Thursday.</li>\n <li>JP Morgan lifted&nbsp;<b>Phillips 66</b>&nbsp;price target from $83 to $93. Phillips 66 shares rose 0.7% to $72.36 on Thursday.</li>\n <li>RBC Capital cut the price target for&nbsp;<b>Cincinnati Financial Corporation</b>&nbsp;from $135 to $130. Cincinnati Financial shares fell 1.7% to $115.23 on Thursday.</li>\n <li>Chardan Capital raised&nbsp;<b>Dicerna Pharmaceuticals, Inc.</b>&nbsp;price target from $28 to $38.25. Dicerna Pharmaceuticals shares rose 0.1% to $38.03 on Thursday.</li>\n <li>Morgan Stanley boosted the price target on&nbsp;<b>Oshkosh Corporation</b>&nbsp;from $134 to $144. Oshkosh shares fell 1.4% to trade at $111.45 on Thursday.</li>\n <li>Wells Fargo cut the price target for&nbsp;<b>Dow Inc.</b>&nbsp;from $75 to $67. Dow shares fell 0.8% to $54.49 on Thursday.</li>\n <li>Barclays raised&nbsp;<b>McKesson Corporation</b>&nbsp;price target from $270 to $290. McKesson shares rose 1.1% to $229.33 on Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-09 23:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>SVB Leerink boosted the price target on&nbsp;<b>Edwards Lifesciences Corporation</b>&nbsp;from $130 to $135. Edwards Lifesciences shares rose 1% to trade at $120.68 on Thursday.</li>\n <li>Keybanc raised&nbsp;<b>The Sherwin-Williams Company</b>&nbsp;price target from $350 to $384. Sherwin-Williams shares rose 1% to $345.68 on Thursday.</li>\n <li>Piper Sandler cut&nbsp;<b>Udemy, Inc.</b>&nbsp;price target from $37 to $34. Udemy shares fell 2% to trade at $20.65 on Thursday.</li>\n <li>Needham lowered the price target on&nbsp;<b>Esperion Therapeutics, Inc.</b>&nbsp;from $20 to $12. Esperion Therapeutics shares dropped 9% to $5.34 on Thursday.</li>\n <li>JP Morgan lifted&nbsp;<b>Phillips 66</b>&nbsp;price target from $83 to $93. Phillips 66 shares rose 0.7% to $72.36 on Thursday.</li>\n <li>RBC Capital cut the price target for&nbsp;<b>Cincinnati Financial Corporation</b>&nbsp;from $135 to $130. Cincinnati Financial shares fell 1.7% to $115.23 on Thursday.</li>\n <li>Chardan Capital raised&nbsp;<b>Dicerna Pharmaceuticals, Inc.</b>&nbsp;price target from $28 to $38.25. Dicerna Pharmaceuticals shares rose 0.1% to $38.03 on Thursday.</li>\n <li>Morgan Stanley boosted the price target on&nbsp;<b>Oshkosh Corporation</b>&nbsp;from $134 to $144. Oshkosh shares fell 1.4% to trade at $111.45 on Thursday.</li>\n <li>Wells Fargo cut the price target for&nbsp;<b>Dow Inc.</b>&nbsp;from $75 to $67. Dow shares fell 0.8% to $54.49 on Thursday.</li>\n <li>Barclays raised&nbsp;<b>McKesson Corporation</b>&nbsp;price target from $270 to $290. McKesson shares rose 1.1% to $229.33 on Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CINF":"辛辛那提金融","OSK":"Oshkosh","EW":"爱德华兹","MCK":"麦克森药物批发","UDMY":"Udemy, Inc.","DRNA":"Dicerna Pharmaceuticals, Inc.","SHW":"宣伟公司","ESPR":"Esperion Therapeutics Inc.","PSX":"Phillips 66","DOW":"陶氏化学"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134628800","content_text":"SVB Leerink boosted the price target on Edwards Lifesciences Corporation from $130 to $135. Edwards Lifesciences shares rose 1% to trade at $120.68 on Thursday.\nKeybanc raised The Sherwin-Williams Company price target from $350 to $384. Sherwin-Williams shares rose 1% to $345.68 on Thursday.\nPiper Sandler cut Udemy, Inc. price target from $37 to $34. Udemy shares fell 2% to trade at $20.65 on Thursday.\nNeedham lowered the price target on Esperion Therapeutics, Inc. from $20 to $12. Esperion Therapeutics shares dropped 9% to $5.34 on Thursday.\nJP Morgan lifted Phillips 66 price target from $83 to $93. Phillips 66 shares rose 0.7% to $72.36 on Thursday.\nRBC Capital cut the price target for Cincinnati Financial Corporation from $135 to $130. Cincinnati Financial shares fell 1.7% to $115.23 on Thursday.\nChardan Capital raised Dicerna Pharmaceuticals, Inc. price target from $28 to $38.25. Dicerna Pharmaceuticals shares rose 0.1% to $38.03 on Thursday.\nMorgan Stanley boosted the price target on Oshkosh Corporation from $134 to $144. Oshkosh shares fell 1.4% to trade at $111.45 on Thursday.\nWells Fargo cut the price target for Dow Inc. from $75 to $67. Dow shares fell 0.8% to $54.49 on Thursday.\nBarclays raised McKesson Corporation price target from $270 to $290. McKesson shares rose 1.1% to $229.33 on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1076,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602329083,"gmtCreate":1638974252750,"gmtModify":1638974252750,"author":{"id":"4088056512769340","authorId":"4088056512769340","name":"Gene7","avatar":"https://static.tigerbbs.com/6104ceb59a974d144154c2afbaf6e10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088056512769340","authorIdStr":"4088056512769340"},"themes":[],"htmlText":"Thanks for the insight. Plz like&nbsp;","listText":"Thanks for the insight. Plz like&nbsp;","text":"Thanks for the insight. Plz like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/602329083","repostId":"1177589023","repostType":4,"repost":{"id":"1177589023","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638964838,"share":"https://www.laohu8.com/m/news/1177589023?lang=&edition=full","pubTime":"2021-12-08 20:00","market":"us","language":"en","title":"Pfizer, BioNTech say third dose neutralizes Omicron variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1177589023","media":"Tiger Newspress","summary":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on ","content":"<p>Pfizer and biontech stocks narrowed their losses&nbsp;in premarket trading&nbsp;after&nbsp;they provided update on Omicron variant.</p>\n<p><img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li>\n <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li>\n <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li>\n <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li>\n</ul>\n<p>Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;today announced results from an initial&nbsp;<i>laboratory</i>&nbsp;study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p>\n<p>Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p>\n<p>A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p>\n<p>“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said&nbsp;<b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p>\n<p>“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said&nbsp;<b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p>\n<p>While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta &amp; Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, BioNTech say third dose neutralizes Omicron variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, BioNTech say third dose neutralizes Omicron variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer and biontech stocks narrowed their losses&nbsp;in premarket trading&nbsp;after&nbsp;they provided update on Omicron variant.</p>\n<p><img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li>\n <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li>\n <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li>\n <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li>\n</ul>\n<p>Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;today announced results from an initial&nbsp;<i>laboratory</i>&nbsp;study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p>\n<p>Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p>\n<p>A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p>\n<p>“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said&nbsp;<b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p>\n<p>“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said&nbsp;<b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p>\n<p>While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta &amp; Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177589023","content_text":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on Omicron variant.\n\n\nPreliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers\nData indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection\nAs 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease\nThe companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022\n\nPfizer Inc. and BioNTech SE today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.\nSera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.\nA more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.\n“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”\n“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”\nWhile these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta & Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1074,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857295821,"gmtCreate":1635526088394,"gmtModify":1635526088394,"author":{"id":"4088056512769340","authorId":"4088056512769340","name":"Gene7","avatar":"https://static.tigerbbs.com/6104ceb59a974d144154c2afbaf6e10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088056512769340","authorIdStr":"4088056512769340"},"themes":[],"htmlText":"Thank you for the info.&nbsp;Plz like.&nbsp;","listText":"Thank you for the info.&nbsp;Plz like.&nbsp;","text":"Thank you for the info. Plz like.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857295821","repostId":"1130577261","repostType":4,"repost":{"id":"1130577261","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635514312,"share":"https://www.laohu8.com/m/news/1130577261?lang=&edition=full","pubTime":"2021-10-29 21:31","market":"us","language":"en","title":"US stocks fall after Big Tech earnings miss, Amazon down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130577261","media":"Tiger Newspress","summary":"Stocks dipped Friday, with investors eyeing a couple of disappointing earnings results fromApple(AAP","content":"<p>Stocks dipped Friday, with investors eyeing a couple of disappointing earnings results fromApple(AAPL) andAmazon(AMZN) that came during an otherwise solid quarterly reporting season from many major companies.</p>\n<p>The S&amp;P 500 fell, pulling back after the blue-chip index set a record closing high on Thursday. The Nasdaq underperformed amid the drawdown in the big technology names. Treasury yields climbed, and the benchmark 10-year yield hovered near 1.6%.</p>\n<p>Amazon shares droppedafter the e-commerce juggernaut missed third-quarter expectations and forecasted a jump in expenses in the fourth quarter due to supply chain disruptions and rising costs for labor, materials and freight. These factors are expected to generate \"several billion dollars of additional costs\" to Amazon in the current quarter, the company said in its earnings statement.</p>\n<p>Peer tech giant Apple also disappointed Wall Street in its fiscal first-quarter results, with key iPhone sales missing expectations even following the launch of its latest iPhone 13 handset series. Shares of Apple's suppliers including Taiwan Semiconductor Manufacturing Co. (TSM), Qualcomm (QCOM) and Broadcom (AVGO) also fell immediately following the results.</p>\n<p>For Wall Street, the results appeared to vindicate concerns that mounting supply chain disruptions, labor costs and materials shortages were impacting companies of all sizes heading into the holiday season, and were creating challenges for corporations to keep pace with rising demand.</p>\n<p>And for Apple, Amazon and some other technology companies, investors have been additionally fearful that these key members of last year's lucrative \"stay-at-home\" trade would be unable to maintain lofty growth rates following a pandemic-induced surge in their businesses. Amazon's sales grew 15% in the third quarter, slowing down markedly from 27% rate in the second quarter.</p>\n<p>“I will agree, they are overvalued,\" Rebecca Felton, Riverfront Investment Group senior market strategist, told Yahoo Finance Live about technology companies on Thursday. \"But remember valuation is a condition, not a catalyst. And the catalyst I think for technology is going to be the consistency both on the top and bottom line.”</p>\n<p>Meanwhile, investors continued to digest a mixed batch of economic data results, which included a weaker-than-expected print on third-quarter gross domestic product. The report, while comprehensive in scope, still offered an only backwards-looking view of state of the economy. Some pundits suggested economic activity had already begun to pick up, helping to underpin companies' performance into the final months of the year and equity prices.</p>\n<p>“I still think the best is yet to come,” Heritage Capital President Paul Schatztold Yahoo Finance on Thursday.“GDP for Q3 is going to be a trough. We’re going to have much stronger growth in Q4 and Q1 of next year, inflation is going to peak in the next six months, supply chain issues strongly moderate by early Q2 of next year. And this rising tide is going to lift most ships.”</p>\n<p>“The economically sensitive trade, whatever you want to call it — reopening, reflation, inflation — that trade is very alive, very well and it’s not over,” he added.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US stocks fall after Big Tech earnings miss, Amazon down 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS stocks fall after Big Tech earnings miss, Amazon down 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-29 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Stocks dipped Friday, with investors eyeing a couple of disappointing earnings results fromApple(AAPL) andAmazon(AMZN) that came during an otherwise solid quarterly reporting season from many major companies.</p>\n<p>The S&amp;P 500 fell, pulling back after the blue-chip index set a record closing high on Thursday. The Nasdaq underperformed amid the drawdown in the big technology names. Treasury yields climbed, and the benchmark 10-year yield hovered near 1.6%.</p>\n<p>Amazon shares droppedafter the e-commerce juggernaut missed third-quarter expectations and forecasted a jump in expenses in the fourth quarter due to supply chain disruptions and rising costs for labor, materials and freight. These factors are expected to generate \"several billion dollars of additional costs\" to Amazon in the current quarter, the company said in its earnings statement.</p>\n<p>Peer tech giant Apple also disappointed Wall Street in its fiscal first-quarter results, with key iPhone sales missing expectations even following the launch of its latest iPhone 13 handset series. Shares of Apple's suppliers including Taiwan Semiconductor Manufacturing Co. (TSM), Qualcomm (QCOM) and Broadcom (AVGO) also fell immediately following the results.</p>\n<p>For Wall Street, the results appeared to vindicate concerns that mounting supply chain disruptions, labor costs and materials shortages were impacting companies of all sizes heading into the holiday season, and were creating challenges for corporations to keep pace with rising demand.</p>\n<p>And for Apple, Amazon and some other technology companies, investors have been additionally fearful that these key members of last year's lucrative \"stay-at-home\" trade would be unable to maintain lofty growth rates following a pandemic-induced surge in their businesses. Amazon's sales grew 15% in the third quarter, slowing down markedly from 27% rate in the second quarter.</p>\n<p>“I will agree, they are overvalued,\" Rebecca Felton, Riverfront Investment Group senior market strategist, told Yahoo Finance Live about technology companies on Thursday. \"But remember valuation is a condition, not a catalyst. And the catalyst I think for technology is going to be the consistency both on the top and bottom line.”</p>\n<p>Meanwhile, investors continued to digest a mixed batch of economic data results, which included a weaker-than-expected print on third-quarter gross domestic product. The report, while comprehensive in scope, still offered an only backwards-looking view of state of the economy. Some pundits suggested economic activity had already begun to pick up, helping to underpin companies' performance into the final months of the year and equity prices.</p>\n<p>“I still think the best is yet to come,” Heritage Capital President Paul Schatztold Yahoo Finance on Thursday.“GDP for Q3 is going to be a trough. We’re going to have much stronger growth in Q4 and Q1 of next year, inflation is going to peak in the next six months, supply chain issues strongly moderate by early Q2 of next year. And this rising tide is going to lift most ships.”</p>\n<p>“The economically sensitive trade, whatever you want to call it — reopening, reflation, inflation — that trade is very alive, very well and it’s not over,” he added.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130577261","content_text":"Stocks dipped Friday, with investors eyeing a couple of disappointing earnings results fromApple(AAPL) andAmazon(AMZN) that came during an otherwise solid quarterly reporting season from many major companies.\nThe S&P 500 fell, pulling back after the blue-chip index set a record closing high on Thursday. The Nasdaq underperformed amid the drawdown in the big technology names. Treasury yields climbed, and the benchmark 10-year yield hovered near 1.6%.\nAmazon shares droppedafter the e-commerce juggernaut missed third-quarter expectations and forecasted a jump in expenses in the fourth quarter due to supply chain disruptions and rising costs for labor, materials and freight. These factors are expected to generate \"several billion dollars of additional costs\" to Amazon in the current quarter, the company said in its earnings statement.\nPeer tech giant Apple also disappointed Wall Street in its fiscal first-quarter results, with key iPhone sales missing expectations even following the launch of its latest iPhone 13 handset series. Shares of Apple's suppliers including Taiwan Semiconductor Manufacturing Co. (TSM), Qualcomm (QCOM) and Broadcom (AVGO) also fell immediately following the results.\nFor Wall Street, the results appeared to vindicate concerns that mounting supply chain disruptions, labor costs and materials shortages were impacting companies of all sizes heading into the holiday season, and were creating challenges for corporations to keep pace with rising demand.\nAnd for Apple, Amazon and some other technology companies, investors have been additionally fearful that these key members of last year's lucrative \"stay-at-home\" trade would be unable to maintain lofty growth rates following a pandemic-induced surge in their businesses. Amazon's sales grew 15% in the third quarter, slowing down markedly from 27% rate in the second quarter.\n“I will agree, they are overvalued,\" Rebecca Felton, Riverfront Investment Group senior market strategist, told Yahoo Finance Live about technology companies on Thursday. \"But remember valuation is a condition, not a catalyst. And the catalyst I think for technology is going to be the consistency both on the top and bottom line.”\nMeanwhile, investors continued to digest a mixed batch of economic data results, which included a weaker-than-expected print on third-quarter gross domestic product. The report, while comprehensive in scope, still offered an only backwards-looking view of state of the economy. Some pundits suggested economic activity had already begun to pick up, helping to underpin companies' performance into the final months of the year and equity prices.\n“I still think the best is yet to come,” Heritage Capital President Paul Schatztold Yahoo Finance on Thursday.“GDP for Q3 is going to be a trough. We’re going to have much stronger growth in Q4 and Q1 of next year, inflation is going to peak in the next six months, supply chain issues strongly moderate by early Q2 of next year. And this rising tide is going to lift most ships.”\n“The economically sensitive trade, whatever you want to call it — reopening, reflation, inflation — that trade is very alive, very well and it’s not over,” he added.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1116,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691296063,"gmtCreate":1640190878449,"gmtModify":1640190879600,"author":{"id":"4088056512769340","authorId":"4088056512769340","name":"Gene7","avatar":"https://static.tigerbbs.com/6104ceb59a974d144154c2afbaf6e10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088056512769340","authorIdStr":"4088056512769340"},"themes":[],"htmlText":"Thanks for the insight. Plz like.&nbsp;[lovely]&nbsp;","listText":"Thanks for the insight. Plz like.&nbsp;[lovely]&nbsp;","text":"Thanks for the insight. Plz like. [lovely]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691296063","repostId":"2193196162","repostType":4,"isVote":1,"tweetType":1,"viewCount":698,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857298267,"gmtCreate":1635525881392,"gmtModify":1635525881392,"author":{"id":"4088056512769340","authorId":"4088056512769340","name":"Gene7","avatar":"https://static.tigerbbs.com/6104ceb59a974d144154c2afbaf6e10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088056512769340","authorIdStr":"4088056512769340"},"themes":[],"htmlText":"[强]&nbsp;","listText":"[强]&nbsp;","text":"[强]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857298267","repostId":"1147653984","repostType":4,"isVote":1,"tweetType":1,"viewCount":630,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":834540213,"gmtCreate":1629815409332,"gmtModify":1633682240611,"author":{"id":"4088056512769340","authorId":"4088056512769340","name":"Gene7","avatar":"https://static.tigerbbs.com/6104ceb59a974d144154c2afbaf6e10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088056512769340","authorIdStr":"4088056512769340"},"themes":[],"htmlText":"[强]&nbsp;Thank you&nbsp;","listText":"[强]&nbsp;Thank you&nbsp;","text":"[强] Thank you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/834540213","repostId":"1183629667","repostType":4,"isVote":1,"tweetType":1,"viewCount":760,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877792253,"gmtCreate":1637980482856,"gmtModify":1637980482856,"author":{"id":"4088056512769340","authorId":"4088056512769340","name":"Gene7","avatar":"https://static.tigerbbs.com/6104ceb59a974d144154c2afbaf6e10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088056512769340","authorIdStr":"4088056512769340"},"themes":[],"htmlText":"Thanks for the insight. Plz like&nbsp;[lovely]&nbsp;","listText":"Thanks for the insight. Plz like&nbsp;[lovely]&nbsp;","text":"Thanks for the insight. Plz like [lovely]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877792253","repostId":"1100178242","repostType":4,"repost":{"id":"1100178242","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1637920008,"share":"https://www.laohu8.com/m/news/1100178242?lang=&edition=full","pubTime":"2021-11-26 17:46","market":"us","language":"en","title":"Worried About A Market Crash? Here Are 3 Things You Can Do","url":"https://stock-news.laohu8.com/highlight/detail?id=1100178242","media":"Benzinga","summary":"COVID-19, a worry that investors had pushed down their list of top concerns in recent months, has so","content":"<p>COVID-19, a worry that investors had pushed down their list of top concerns in recent months, has soared back up to the number&nbsp;one&nbsp;spot as a new variant spreads across South Africa.</p>\n<p>Asia stocks outside Japan slid over 2%, Europe and U.S. stock futures are down sharply, oil prices drops almost 5%, the safe-haven yen is up around three-quarters of a percent, and U.S. Treasury yields are down almost 10 basis points.</p>\n<p>Little is known of the variant, detected in South Africa, Botswana and Hong Kong, but scientists reckon it has an unusual combination of mutations and may be able to evade immune responses or make it more transmissible.</p>\n<p>The news comes as Europe already battles a resurgent COVID-19 outbreak, triggering fresh restrictions that raise uncertainty over the near-term economic outlook.</p>\n<p>Thin liquidity following Thursday's U.S. Thanksgiving Day holiday likely exacerbates price moves for sure, but there's little doubt overnight headlines have taken markets by surprise on Friday.</p>\n<p>It’s been another great year for investors, with the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b>&nbsp;up another 25.4% on the year. The S&amp;P 500 has also made it more than a year since its last 10% correction, and some investors are growing concerned that a combination of historically high stock valuations, rising inflation,&nbsp;the&nbsp;COVID-19 variant and the possibility that&nbsp;aggressive Federal Reserve tightening could trigger a market crash in the next couple of quarters.</p>\n<p><img src=\"https://static.tigerbbs.com/1f999347452cfb2fdd30570431642cb9\" tg-width=\"685\" tg-height=\"375\" referrerpolicy=\"no-referrer\"></p>\n<p>Historically, the S&amp;P 500 has averaged about one 10% pullback per yearsince 1950. Long-term investors have no reason to fear temporary market pullbacks, but there are ways to prepare for the next stock market crash to reduce your risk and take advantage of the potential buying opportunity. Here are three things to do before the next stock market crash.</p>\n<p><b>1. Diversify Your Portfolio</b></p>\n<p>Not all market sectors and asset classes take the same hit when the stock market crashes, but it’s difficult to predict beforehand which stocks will be hit hardest. The market crash in 2008 hit bank and housing stocks hardest, while the crash in 2020 was particularly bad for travel and retail stocks. Growth stocks also tend to take a harder hit than value stocks during market crashes. By diversifying your portfolio into different types of stocks, bonds, commodities and other investments, you are ensuring that your portfolio won’t be overexposed to the worst parts of the next market crash or underexposed to any investments that may avoid the sell-off.</p>\n<p><b>2. Raise Cash</b></p>\n<p>There have been countless pullbacks, crashes and recessions throughout history. One strategy that has worked every single time for long-term investors during those periods is buying the dip. But to buy the dip, you must have cash or margin available.</p>\n<p>If you are 100% invested, your hands will be tied and your only option may be tosell stockat the worst possible time. Market crashes are nearly impossible to predict, so there’s no need to dump all your stocks now and transition to all cash. But raising the amount of cash in your account to 10%, 20% or whatever level makes you feel more comfortable allows you to be opportunistic when the next crash happens.</p>\n<p><b>3. Maintain A Watch List</b></p>\n<p>Investors tend to not make the best, most rational decisions during the worst of a stock market crash. It’s best if you have a plan of action before the crash so that you aren’t trying to make emotional decisions when it seems like the sky is falling.</p>\n<p>Before the stock market turns south, make a list of stocks you may potentially be interested in buying on the dip. Research these companies and vet them prior to the crash so that all you have to do when the opportunity to buy the dip arises is click that “buy” button.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Worried About A Market Crash? Here Are 3 Things You Can Do</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWorried About A Market Crash? Here Are 3 Things You Can Do\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-11-26 17:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>COVID-19, a worry that investors had pushed down their list of top concerns in recent months, has soared back up to the number&nbsp;one&nbsp;spot as a new variant spreads across South Africa.</p>\n<p>Asia stocks outside Japan slid over 2%, Europe and U.S. stock futures are down sharply, oil prices drops almost 5%, the safe-haven yen is up around three-quarters of a percent, and U.S. Treasury yields are down almost 10 basis points.</p>\n<p>Little is known of the variant, detected in South Africa, Botswana and Hong Kong, but scientists reckon it has an unusual combination of mutations and may be able to evade immune responses or make it more transmissible.</p>\n<p>The news comes as Europe already battles a resurgent COVID-19 outbreak, triggering fresh restrictions that raise uncertainty over the near-term economic outlook.</p>\n<p>Thin liquidity following Thursday's U.S. Thanksgiving Day holiday likely exacerbates price moves for sure, but there's little doubt overnight headlines have taken markets by surprise on Friday.</p>\n<p>It’s been another great year for investors, with the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b>&nbsp;up another 25.4% on the year. The S&amp;P 500 has also made it more than a year since its last 10% correction, and some investors are growing concerned that a combination of historically high stock valuations, rising inflation,&nbsp;the&nbsp;COVID-19 variant and the possibility that&nbsp;aggressive Federal Reserve tightening could trigger a market crash in the next couple of quarters.</p>\n<p><img src=\"https://static.tigerbbs.com/1f999347452cfb2fdd30570431642cb9\" tg-width=\"685\" tg-height=\"375\" referrerpolicy=\"no-referrer\"></p>\n<p>Historically, the S&amp;P 500 has averaged about one 10% pullback per yearsince 1950. Long-term investors have no reason to fear temporary market pullbacks, but there are ways to prepare for the next stock market crash to reduce your risk and take advantage of the potential buying opportunity. Here are three things to do before the next stock market crash.</p>\n<p><b>1. Diversify Your Portfolio</b></p>\n<p>Not all market sectors and asset classes take the same hit when the stock market crashes, but it’s difficult to predict beforehand which stocks will be hit hardest. The market crash in 2008 hit bank and housing stocks hardest, while the crash in 2020 was particularly bad for travel and retail stocks. Growth stocks also tend to take a harder hit than value stocks during market crashes. By diversifying your portfolio into different types of stocks, bonds, commodities and other investments, you are ensuring that your portfolio won’t be overexposed to the worst parts of the next market crash or underexposed to any investments that may avoid the sell-off.</p>\n<p><b>2. Raise Cash</b></p>\n<p>There have been countless pullbacks, crashes and recessions throughout history. One strategy that has worked every single time for long-term investors during those periods is buying the dip. But to buy the dip, you must have cash or margin available.</p>\n<p>If you are 100% invested, your hands will be tied and your only option may be tosell stockat the worst possible time. Market crashes are nearly impossible to predict, so there’s no need to dump all your stocks now and transition to all cash. But raising the amount of cash in your account to 10%, 20% or whatever level makes you feel more comfortable allows you to be opportunistic when the next crash happens.</p>\n<p><b>3. Maintain A Watch List</b></p>\n<p>Investors tend to not make the best, most rational decisions during the worst of a stock market crash. It’s best if you have a plan of action before the crash so that you aren’t trying to make emotional decisions when it seems like the sky is falling.</p>\n<p>Before the stock market turns south, make a list of stocks you may potentially be interested in buying on the dip. Research these companies and vet them prior to the crash so that all you have to do when the opportunity to buy the dip arises is click that “buy” button.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100178242","content_text":"COVID-19, a worry that investors had pushed down their list of top concerns in recent months, has soared back up to the number one spot as a new variant spreads across South Africa.\nAsia stocks outside Japan slid over 2%, Europe and U.S. stock futures are down sharply, oil prices drops almost 5%, the safe-haven yen is up around three-quarters of a percent, and U.S. Treasury yields are down almost 10 basis points.\nLittle is known of the variant, detected in South Africa, Botswana and Hong Kong, but scientists reckon it has an unusual combination of mutations and may be able to evade immune responses or make it more transmissible.\nThe news comes as Europe already battles a resurgent COVID-19 outbreak, triggering fresh restrictions that raise uncertainty over the near-term economic outlook.\nThin liquidity following Thursday's U.S. Thanksgiving Day holiday likely exacerbates price moves for sure, but there's little doubt overnight headlines have taken markets by surprise on Friday.\nIt’s been another great year for investors, with the SPDR S&P 500 ETF Trust up another 25.4% on the year. The S&P 500 has also made it more than a year since its last 10% correction, and some investors are growing concerned that a combination of historically high stock valuations, rising inflation, the COVID-19 variant and the possibility that aggressive Federal Reserve tightening could trigger a market crash in the next couple of quarters.\n\nHistorically, the S&P 500 has averaged about one 10% pullback per yearsince 1950. Long-term investors have no reason to fear temporary market pullbacks, but there are ways to prepare for the next stock market crash to reduce your risk and take advantage of the potential buying opportunity. Here are three things to do before the next stock market crash.\n1. Diversify Your Portfolio\nNot all market sectors and asset classes take the same hit when the stock market crashes, but it’s difficult to predict beforehand which stocks will be hit hardest. The market crash in 2008 hit bank and housing stocks hardest, while the crash in 2020 was particularly bad for travel and retail stocks. Growth stocks also tend to take a harder hit than value stocks during market crashes. By diversifying your portfolio into different types of stocks, bonds, commodities and other investments, you are ensuring that your portfolio won’t be overexposed to the worst parts of the next market crash or underexposed to any investments that may avoid the sell-off.\n2. Raise Cash\nThere have been countless pullbacks, crashes and recessions throughout history. One strategy that has worked every single time for long-term investors during those periods is buying the dip. But to buy the dip, you must have cash or margin available.\nIf you are 100% invested, your hands will be tied and your only option may be tosell stockat the worst possible time. Market crashes are nearly impossible to predict, so there’s no need to dump all your stocks now and transition to all cash. But raising the amount of cash in your account to 10%, 20% or whatever level makes you feel more comfortable allows you to be opportunistic when the next crash happens.\n3. Maintain A Watch List\nInvestors tend to not make the best, most rational decisions during the worst of a stock market crash. It’s best if you have a plan of action before the crash so that you aren’t trying to make emotional decisions when it seems like the sky is falling.\nBefore the stock market turns south, make a list of stocks you may potentially be interested in buying on the dip. Research these companies and vet them prior to the crash so that all you have to do when the opportunity to buy the dip arises is click that “buy” button.","news_type":1},"isVote":1,"tweetType":1,"viewCount":819,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609000596,"gmtCreate":1638202355191,"gmtModify":1638202355389,"author":{"id":"4088056512769340","authorId":"4088056512769340","name":"Gene7","avatar":"https://static.tigerbbs.com/6104ceb59a974d144154c2afbaf6e10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088056512769340","authorIdStr":"4088056512769340"},"themes":[],"htmlText":"Thank you for the insight. Plz like.&nbsp;[lovely]&nbsp;","listText":"Thank you for the insight. Plz like.&nbsp;[lovely]&nbsp;","text":"Thank you for the insight. Plz like. [lovely]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609000596","repostId":"1115824573","repostType":4,"repost":{"id":"1115824573","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638191842,"share":"https://www.laohu8.com/m/news/1115824573?lang=&edition=full","pubTime":"2021-11-29 21:17","market":"us","language":"en","title":"Toplines Before US Market Open on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1115824573","media":"Tiger Newspress","summary":"U.S. stock index futures jumped on Monday as investors rushed in to take advantage of steep virus-dr","content":"<p>U.S. stock index futures jumped on Monday as investors rushed in to take advantage of steep virus-driven losses while awaiting more details on the severity of the Omicron coronavirus variant.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 226 points, or 0.65%. S&amp;P 500 e-minis were up 37 points, or 0.81% and Nasdaq 100 e-minis were up 148.75 points, or 0.93%.</p>\n<p><img src=\"https://static.tigerbbs.com/4e047384eb051a409672b8ce439d9f38\" tg-width=\"1080\" tg-height=\"392\" referrerpolicy=\"no-referrer\"></p>\n<p>Wall Street indexes had slumped between 2% and 3.5% on Friday after news of the variant triggered a global selloff, as countries introduced new travel curbs on fears it could resist vaccinations and upend a nascent economic reopening.</p>\n<p>President Joe Biden is due to update the public on the variant and the United States' response later in the day, the White House said.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p><b>Moderna</b>&nbsp;— Shares of the vaccine maker continued their rally, jumping more than 10% in early morning trading Monday after gaining 20% on Friday. On Sunday the company’s chief medical officer said Moderna&nbsp;could roll out a reformulated vaccine&nbsp;against the omicron variant of Covid early next year.</p>\n<p><b>Li Auto</b> —&nbsp;U.S.-listed shares of Li Auto rose 8.5%&nbsp;in premarket trading. Li Auto&nbsp;reported adjusted earnings of 3 cents a share from $1.21 billion in sales. Wall Street was looking for a 3-cent loss from $1.13 billion in sales. At this point, earnings are less important that sales for Li. The company is still growing rapidly. Sales in the third quarter rose more than 209% year over year.</p>\n<p><b>Tesla</b>&nbsp;—&nbsp;The German automotive news outlet Automobilwoche&nbsp;reported Monday that Tesla’s new manufacturing facility in that country will start production in December.Tesla&nbsp;shares&nbsp;rallied&nbsp;1.5%&nbsp;in premarket trading.</p>\n<p><b>Apple</b>&nbsp;—&nbsp;Apple&nbsp;rose 1.5% after HSBC raised its price target on the iPhone maker's stock.</p>\n<p><b>Airlines</b> — Major airlines ticked up as investors bought the dip following&nbsp;new travel suspensions in Asia and Europe, in response to the newly discovered omicron variant of Covid-19.United,Delta&nbsp;and&nbsp;American Airlines&nbsp;each gained about 1%, after losing about 7% Friday. Travel booking site&nbsp;Expedia&nbsp;also rose, about 2%.</p>\n<p><b>Cruise lines</b> —Carnival,Royal Caribbean Cruises&nbsp;and&nbsp;Norwegian Cruise Line Holdings&nbsp;each rose more than 3% amid the broader rebound in travel stocks from Friday’s omicron-driven sell-off.</p>\n<p><b>Allbirds</b>— Shares of the shoe manufacturer rose 2.5% after several analysts initiated coverage of the stock. Morgan Stanley and Bank of America both posted a price target of $23, implying 16% upside to Friday’s close.</p>\n<p><b>Coinbase</b>— The cryptocurrency exchange’s shares rose more than 2% as the price of bitcoin rebounded, after selling off with the broader equities market on Friday. Other crypto-related equities got a lift too, with&nbsp;Microstrategy&nbsp;rising 3.4%.Tesla&nbsp;and&nbsp;Square&nbsp;added more than 1%.</p>\n<p><b>Zoom Video</b>— Zoom shares fell almost 2%, moving in the opposite direction of travel stocks and following a 5.7% jump on Friday. Other stay-at-home stocks dipped slightly Monday morning too, including&nbsp;Peloton,Netflix&nbsp;and&nbsp;Teladoc.</p>\n<p><b>Merck</b>— The pharmaceutical company’s shares fell 1.8% after Citi downgraded its stock to neutral from buy, saying development struggles for the company’s HIV drug islatravir will hurt Merck’s long-term potential.</p>\n<p><b>Wynn Resorts,Las Vegas Sands</b>— The Macao gaming sector is lower after Alvin Chau, the head of Macau’s biggest casino junket operator, and 10 others were arrested over allegedly illegal gambling platforms targeting mainland Chinese, according to a report by the South China Morning Post.Wynn&nbsp;fell 1.9% and&nbsp;Las Vegas Sands&nbsp;fell 1.2%</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-29 21:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock index futures jumped on Monday as investors rushed in to take advantage of steep virus-driven losses while awaiting more details on the severity of the Omicron coronavirus variant.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 226 points, or 0.65%. S&amp;P 500 e-minis were up 37 points, or 0.81% and Nasdaq 100 e-minis were up 148.75 points, or 0.93%.</p>\n<p><img src=\"https://static.tigerbbs.com/4e047384eb051a409672b8ce439d9f38\" tg-width=\"1080\" tg-height=\"392\" referrerpolicy=\"no-referrer\"></p>\n<p>Wall Street indexes had slumped between 2% and 3.5% on Friday after news of the variant triggered a global selloff, as countries introduced new travel curbs on fears it could resist vaccinations and upend a nascent economic reopening.</p>\n<p>President Joe Biden is due to update the public on the variant and the United States' response later in the day, the White House said.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p><b>Moderna</b>&nbsp;— Shares of the vaccine maker continued their rally, jumping more than 10% in early morning trading Monday after gaining 20% on Friday. On Sunday the company’s chief medical officer said Moderna&nbsp;could roll out a reformulated vaccine&nbsp;against the omicron variant of Covid early next year.</p>\n<p><b>Li Auto</b> —&nbsp;U.S.-listed shares of Li Auto rose 8.5%&nbsp;in premarket trading. Li Auto&nbsp;reported adjusted earnings of 3 cents a share from $1.21 billion in sales. Wall Street was looking for a 3-cent loss from $1.13 billion in sales. At this point, earnings are less important that sales for Li. The company is still growing rapidly. Sales in the third quarter rose more than 209% year over year.</p>\n<p><b>Tesla</b>&nbsp;—&nbsp;The German automotive news outlet Automobilwoche&nbsp;reported Monday that Tesla’s new manufacturing facility in that country will start production in December.Tesla&nbsp;shares&nbsp;rallied&nbsp;1.5%&nbsp;in premarket trading.</p>\n<p><b>Apple</b>&nbsp;—&nbsp;Apple&nbsp;rose 1.5% after HSBC raised its price target on the iPhone maker's stock.</p>\n<p><b>Airlines</b> — Major airlines ticked up as investors bought the dip following&nbsp;new travel suspensions in Asia and Europe, in response to the newly discovered omicron variant of Covid-19.United,Delta&nbsp;and&nbsp;American Airlines&nbsp;each gained about 1%, after losing about 7% Friday. Travel booking site&nbsp;Expedia&nbsp;also rose, about 2%.</p>\n<p><b>Cruise lines</b> —Carnival,Royal Caribbean Cruises&nbsp;and&nbsp;Norwegian Cruise Line Holdings&nbsp;each rose more than 3% amid the broader rebound in travel stocks from Friday’s omicron-driven sell-off.</p>\n<p><b>Allbirds</b>— Shares of the shoe manufacturer rose 2.5% after several analysts initiated coverage of the stock. Morgan Stanley and Bank of America both posted a price target of $23, implying 16% upside to Friday’s close.</p>\n<p><b>Coinbase</b>— The cryptocurrency exchange’s shares rose more than 2% as the price of bitcoin rebounded, after selling off with the broader equities market on Friday. Other crypto-related equities got a lift too, with&nbsp;Microstrategy&nbsp;rising 3.4%.Tesla&nbsp;and&nbsp;Square&nbsp;added more than 1%.</p>\n<p><b>Zoom Video</b>— Zoom shares fell almost 2%, moving in the opposite direction of travel stocks and following a 5.7% jump on Friday. Other stay-at-home stocks dipped slightly Monday morning too, including&nbsp;Peloton,Netflix&nbsp;and&nbsp;Teladoc.</p>\n<p><b>Merck</b>— The pharmaceutical company’s shares fell 1.8% after Citi downgraded its stock to neutral from buy, saying development struggles for the company’s HIV drug islatravir will hurt Merck’s long-term potential.</p>\n<p><b>Wynn Resorts,Las Vegas Sands</b>— The Macao gaming sector is lower after Alvin Chau, the head of Macau’s biggest casino junket operator, and 10 others were arrested over allegedly illegal gambling platforms targeting mainland Chinese, according to a report by the South China Morning Post.Wynn&nbsp;fell 1.9% and&nbsp;Las Vegas Sands&nbsp;fell 1.2%</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","UAL":"联合大陆航空","AAPL":"苹果","LVS":"金沙集团","ZM":"Zoom","BIRD":"Allbirds, Inc.",".SPX":"S&P 500 Index","DAL":"达美航空","WYNN":"永利度假村","TSLA":"特斯拉",".IXIC":"NASDAQ Composite","LI":"理想汽车",".DJI":"道琼斯","MRK":"默沙东","COIN":"Coinbase Global, Inc.","CCL":"嘉年华邮轮","RCL":"皇家加勒比邮轮","NCLH":"挪威邮轮","AAL":"美国航空"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115824573","content_text":"U.S. stock index futures jumped on Monday as investors rushed in to take advantage of steep virus-driven losses while awaiting more details on the severity of the Omicron coronavirus variant.\nAt 8:00 a.m. ET, Dow e-minis were up 226 points, or 0.65%. S&P 500 e-minis were up 37 points, or 0.81% and Nasdaq 100 e-minis were up 148.75 points, or 0.93%.\n\nWall Street indexes had slumped between 2% and 3.5% on Friday after news of the variant triggered a global selloff, as countries introduced new travel curbs on fears it could resist vaccinations and upend a nascent economic reopening.\nPresident Joe Biden is due to update the public on the variant and the United States' response later in the day, the White House said.\nStocks making the biggest moves premarket:\nModerna — Shares of the vaccine maker continued their rally, jumping more than 10% in early morning trading Monday after gaining 20% on Friday. On Sunday the company’s chief medical officer said Moderna could roll out a reformulated vaccine against the omicron variant of Covid early next year.\nLi Auto — U.S.-listed shares of Li Auto rose 8.5% in premarket trading. Li Auto reported adjusted earnings of 3 cents a share from $1.21 billion in sales. Wall Street was looking for a 3-cent loss from $1.13 billion in sales. At this point, earnings are less important that sales for Li. The company is still growing rapidly. Sales in the third quarter rose more than 209% year over year.\nTesla — The German automotive news outlet Automobilwoche reported Monday that Tesla’s new manufacturing facility in that country will start production in December.Tesla shares rallied 1.5% in premarket trading.\nApple — Apple rose 1.5% after HSBC raised its price target on the iPhone maker's stock.\nAirlines — Major airlines ticked up as investors bought the dip following new travel suspensions in Asia and Europe, in response to the newly discovered omicron variant of Covid-19.United,Delta and American Airlines each gained about 1%, after losing about 7% Friday. Travel booking site Expedia also rose, about 2%.\nCruise lines —Carnival,Royal Caribbean Cruises and Norwegian Cruise Line Holdings each rose more than 3% amid the broader rebound in travel stocks from Friday’s omicron-driven sell-off.\nAllbirds— Shares of the shoe manufacturer rose 2.5% after several analysts initiated coverage of the stock. Morgan Stanley and Bank of America both posted a price target of $23, implying 16% upside to Friday’s close.\nCoinbase— The cryptocurrency exchange’s shares rose more than 2% as the price of bitcoin rebounded, after selling off with the broader equities market on Friday. Other crypto-related equities got a lift too, with Microstrategy rising 3.4%.Tesla and Square added more than 1%.\nZoom Video— Zoom shares fell almost 2%, moving in the opposite direction of travel stocks and following a 5.7% jump on Friday. Other stay-at-home stocks dipped slightly Monday morning too, including Peloton,Netflix and Teladoc.\nMerck— The pharmaceutical company’s shares fell 1.8% after Citi downgraded its stock to neutral from buy, saying development struggles for the company’s HIV drug islatravir will hurt Merck’s long-term potential.\nWynn Resorts,Las Vegas Sands— The Macao gaming sector is lower after Alvin Chau, the head of Macau’s biggest casino junket operator, and 10 others were arrested over allegedly illegal gambling platforms targeting mainland Chinese, according to a report by the South China Morning Post.Wynn fell 1.9% and Las Vegas Sands fell 1.2%","news_type":1},"isVote":1,"tweetType":1,"viewCount":935,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}